Pharvaris N.V. PHVS

$32.82 +0.87 (2.72%)

Valuation

Market cap
2,378,889,000
Revenue TTM
$0
Net income TTM
$-198,790,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
381,000
Avg volume
826,316
Day's range
$31.74 – $32.86
Shares out
65,408,000
Stochastic %K
99%
Beta
-2.33
Analysts
Strong Sell
Price target
$59.85

Price

Company profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du...

Show more

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Phone
31 712036410
Website
https://pharvaris.com
Address
Grafenauweg 8, Zug, Switzerland

Latest news

Stocktwits

De_Monitor Oct 24, 7:41 AM
$PHVS 5 months to go!
0 replies
JFais Oct 23, 2:04 PM
$PHAR (L) Under the radar growth story in the rare disease space Encouraging rebound in Ruconest revenues, despite oral HAE competitors $BCRX $KALV $PHVS Joenja sales +58%, accelerating 2027-2028 via international launch +label expansion to younger patients (notes in Chat) *Caveat, very low trading volume
1 replies
notreload_ai Oct 23, 12:13 PM
Raymond James, Cantor, BofA and Citizens issue positive ratings on $CAMP, $BNTC, $IMUX, $PHVS and $MBOT, citing clinical catalysts and upside. https://notreload.xyz/xy/positive-initiations-on-camp-bntc-imux-phvs-and-mbot/
0 replies
DontBanMeAgain Oct 21, 1:39 PM
$PHVS The pellet form of Orladeyo results are basically the same as PHVS, but BCRX already has thorough market penetration. It seems Pharvaris shares are still way overpriced, and BCRX shares laughably undervalued.
2 replies
Fergus20 Oct 19, 5:13 PM
$BCRX why is $PHVS up more than this? They’re years away from any actual revenue.
1 replies
CH_Expat Oct 16, 3:59 PM
$PHVS Haters will say it is all bios, but it is not. It is exactly quality stocks that get slaughtered. 1.5b MC and I will dip a toe in.
0 replies
Fergus20 Oct 13, 10:57 PM
$PHVS BCRX is better you absolute MORONS!!!
0 replies
CH_Expat Oct 8, 2:59 PM
$PHVS Getting closer.
0 replies